Skip to main content

Table 1 Patient characteristics

From: Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

   Metronomic arm Conventional arm P
   No % No %  
Median age (range)   46 (35-73) 51 (33-73) 0.1040
ER status + 22 73.3 18 60.0 0.3950
  - 7 23.3 11 36.6  
Her-2 status + 3 10.0 4 13.3 1.0000
  - 22 73.3 24 80.0  
Primary tumor T1, T2 26 86.7 30 100.0 0.1120
  T3, T4 4 13.3 0 0  
Disease free interval* >2 years 23 76.7 20 66.7 0.5670
  ≤ 2 years 7 23.3 10 33.3  
Lymph node 0 ≤ N ≤ 3 25 83.3 22 73.3 0.5320
  N>3 5 16.7 8 26.7  
Previous radiotherapy yes 18 60.0 20 66.7 0.7890
  no 12 40.0 10 33.3  
Primary histology IDC 29 96.7 28 93.3 1.0000
  ILC 1 3.3 2 6.7  
Grade 1 9 30.0 6 20.0 0.7180
  2 14 46.7 16 53.3  
  3 4 13.3 3 10.0  
Menopausal pre 17 56.7 14 46.7 0.6060
  post 13 43.3 16 53.3  
Previous chemotherapy regimen ≤ 2 26 86.7 22 73.3 0.3330
  >2 4 13.3 8 26.7  
Bone metastasis sites 1 11 36.7 9 30.0 0.7850
  ≥ 2 19 63.3 21 70.0  
  1. * Disease free interval = date from surgery to first recurrence